Associations of Cathepsins with Pulmonary Arterial Hypertension Mediated by Circulating Metabolites: A Mendelian Randomization Study

Overview

Journal Medicine (Baltimore)

Date 2025 Jan 24

PMID 39854747

Authors

Shasha Yang

Qiong Chen

Baishuang Yang

Affiliations

Soon will be listed here.

Abstract

The correlation between cathepsins and pulmonary arterial hypertension (PAH) is well-established, but the causative link between them remains uncertain. This study aimed to explore the causal role of circulating metabolites mediating cathepsins in PAH using Mendelian randomization (MR). A 2-sample 2-step MR method was used to identify causal relationship between cathepsins and PAH; causal relationship between circulating metabolites and PAH; and mediated effects of these circulating metabolites. GWAS summary statistics on circulating metabolites were from the Canadian longitudinal study on aging cohort, human plasma cathepsins from The INTERVAL study, and PAH from FinnGen version R10. Two-sample MR analyses involving 9 cathepsins (cathepsin B, E, F, G, H, L2, O, S, and Z). Cathepsin S was associated with high risk of PAH (OR: 1.346, 95% CI: 1.039-1.742, P = .024), and positively with circulating metabolite 1-oleoylglycerol (18:1) levels (OR: 1.062, 95% CI: 1.018-1.108, P = .005). Finally, mediation analysis showed evidence of mediated effect of cathepsin S on PAH through 1-oleoylglycerol (18:1) levels (OR: 0.062, CI: 0.0183-0.106) with a mediated proportion of 20.9% of the total effect. This study reveals cathepsin S increases the risk of PAH mediating by circulating metabolite 1-oleoylglycerol (18:1) levels.

Citing Articles

Bidirectional causal relationships between the skin microbiome and psoriasis: Insights from Mendelian randomization analysis.

Xu S, Yang K, Qiu J, Zhong J, Xian D Medicine (Baltimore). 2025; 104(10):e41736.

PMID: 40068044 PMC: 11903008. DOI: 10.1097/MD.0000000000041736.

References

Ulrich A, Wu Y, Draisma H, Wharton J, Swietlik E, Cebola I . Blood DNA methylation profiling identifies cathepsin Z dysregulation in pulmonary arterial hypertension. Nat Commun. 2024; 15(1):330. PMC: 10771427. DOI: 10.1038/s41467-023-44683-0. View

Wang Q, Dai H, Hou T, Hou Y, Wang T, Lin H . Dissecting Causal Relationships Between Gut Microbiota, Blood Metabolites, and Stroke: A Mendelian Randomization Study. J Stroke. 2023; 25(3):350-360. PMC: 10574297. DOI: 10.5853/jos.2023.00381. View

Smyth P, Sasiwachirangkul J, Williams R, Scott C . Cathepsin S (CTSS) activity in health and disease - A treasure trove of untapped clinical potential. Mol Aspects Med. 2022; 88:101106. DOI: 10.1016/j.mam.2022.101106. View

Cho Y, Haycock P, Sanderson E, Gaunt T, Zheng J, Morris A . Exploiting horizontal pleiotropy to search for causal pathways within a Mendelian randomization framework. Nat Commun. 2020; 11(1):1010. PMC: 7035387. DOI: 10.1038/s41467-020-14452-4. View

Legchenko E, Chouvarine P, Borchert P, Fernandez-Gonzalez A, Snay E, Meier M . PPARγ agonist pioglitazone reverses pulmonary hypertension and prevents right heart failure via fatty acid oxidation. Sci Transl Med. 2018; 10(438). DOI: 10.1126/scitranslmed.aao0303. View

Maron B, Abman S, Elliott C, Frantz R, Hopper R, Horn E . Pulmonary Arterial Hypertension: Diagnosis, Treatment, and Novel Advances. Am J Respir Crit Care Med. 2021; 203(12):1472-1487. PMC: 8483220. DOI: 10.1164/rccm.202012-4317SO. View

Bowden J, Davey Smith G, Burgess S . Mendelian randomization with invalid instruments: effect estimation and bias detection through Egger regression. Int J Epidemiol. 2015; 44(2):512-25. PMC: 4469799. DOI: 10.1093/ije/dyv080. View

Yao L, Yang Y, He G, Ou C, Wang L, Liu K . Global Proteomics Deciphered Novel-Function of Osthole Against Pulmonary Arterial Hypertension. Sci Rep. 2018; 8(1):5556. PMC: 5882969. DOI: 10.1038/s41598-018-23775-8. View

Houben T, Oligschlaeger Y, Hendrikx T, Bitorina A, Walenbergh S, van Gorp P . Cathepsin D regulates lipid metabolism in murine steatohepatitis. Sci Rep. 2017; 7(1):3494. PMC: 5471235. DOI: 10.1038/s41598-017-03796-5. View

10.

Pi H, Xia L, Ralph D, Rayner S, Shojaie A, Leary P . Metabolomic Signatures Associated With Pulmonary Arterial Hypertension Outcomes. Circ Res. 2023; 132(3):254-266. PMC: 9904878. DOI: 10.1161/CIRCRESAHA.122.321923. View

11.

Talati M, Hemnes A . Fatty acid metabolism in pulmonary arterial hypertension: role in right ventricular dysfunction and hypertrophy. Pulm Circ. 2015; 5(2):269-78. PMC: 4449237. DOI: 10.1086/681227. View

12.

Hassoun P . Pulmonary Arterial Hypertension. N Engl J Med. 2021; 385(25):2361-2376. DOI: 10.1056/NEJMra2000348. View

13.

Yang Y, Zhang S, Zhou Q, Zhang C, Gao Y, Wang H . Discovery of highly selective and orally available benzimidazole-based phosphodiesterase 10 inhibitors with improved solubility and pharmacokinetic properties for treatment of pulmonary arterial hypertension. Acta Pharm Sin B. 2020; 10(12):2339-2347. PMC: 7745062. DOI: 10.1016/j.apsb.2020.04.003. View

14.

de Jesus D, DeVallance E, Li Y, Falabella M, Guimaraes D, Shiva S . Nox1/Ref-1-mediated activation of CREB promotes Gremlin1-driven endothelial cell proliferation and migration. Redox Biol. 2019; 22:101138. PMC: 6395885. DOI: 10.1016/j.redox.2019.101138. View

15.

Li J, Tang M, Gao X, Tian S, Liu W . Mendelian randomization analyses explore the relationship between cathepsins and lung cancer. Commun Biol. 2023; 6(1):1019. PMC: 10560205. DOI: 10.1038/s42003-023-05408-7. View

16.

Brown R, Nath S, Lora A, Samaha G, Elgamal Z, Kaiser R . Cathepsin S: investigating an old player in lung disease pathogenesis, comorbidities, and potential therapeutics. Respir Res. 2020; 21(1):111. PMC: 7216426. DOI: 10.1186/s12931-020-01381-5. View

17.

Bowden J, Davey Smith G, Haycock P, Burgess S . Consistent Estimation in Mendelian Randomization with Some Invalid Instruments Using a Weighted Median Estimator. Genet Epidemiol. 2016; 40(4):304-14. PMC: 4849733. DOI: 10.1002/gepi.21965. View

18.

Rhodes C, Ghataorhe P, Wharton J, Rue-Albrecht K, Hadinnapola C, Watson G . Plasma Metabolomics Implicates Modified Transfer RNAs and Altered Bioenergetics in the Outcomes of Pulmonary Arterial Hypertension. Circulation. 2016; 135(5):460-475. PMC: 5287439. DOI: 10.1161/CIRCULATIONAHA.116.024602. View

19.

Chen Y, Lu T, Pettersson-Kymmer U, Stewart I, Butler-Laporte G, Nakanishi T . Genomic atlas of the plasma metabolome prioritizes metabolites implicated in human diseases. Nat Genet. 2023; 55(1):44-53. PMC: 7614162. DOI: 10.1038/s41588-022-01270-1. View

20.

Carter A, Sanderson E, Hammerton G, Richmond R, Davey Smith G, Heron J . Mendelian randomisation for mediation analysis: current methods and challenges for implementation. Eur J Epidemiol. 2021; 36(5):465-478. PMC: 8159796. DOI: 10.1007/s10654-021-00757-1. View